Radiation Therapy for Skin Cancer: When Is It Used

Radiation therapy for skin cancer represents an important treatment modality for non-melanoma skin cancers and advanced melanoma, utilizing ionizing radiation to cause DNA damage and tumor cell death. This non-surgical option is valuable for medically inoperable patients, tumors in cosmetically sensitive locations, and extensive field cancerization. Modern radiation techniques (intensity-modulated radiation therapy, volumetric-modulated arc therapy, proton therapy) provide superior tumor targeting and normal tissue sparing compared to older techniques. Understanding indications, mechanisms, efficacy, and adverse effects enables informed patient decision-making and optimizes treatment outcomes. Radiation therapy is increasingly combined with immunotherapy and targeted therapy for advanced melanoma, showing promise for improved outcomes compared to historical chemotherapy approaches.

Radiation Techniques and Dosing

Photon-Based Therapy: X-rays or gamma radiation generate free radicals causing indirect DNA damage. Conventional external beam therapy delivers 1.8-3.0 Gy fractions, 5 days weekly for 2-6 weeks total (total doses 30-60 Gy). Intensity-modulated radiation therapy (IMRT) shapes radiation beams to tumor contours, optimizing dose to tumor while sparing surrounding tissue.

Particle-Based Therapy: Protons and heavy ions create direct ionization with minimal exit dose (Bragg peak effect), potentially improving therapeutic ratio. Proton therapy is beneficial for tumors near critical structures (eyes, brain, parotid gland). However, cost and access limitations restrict proton therapy to selected patients.

Hypofractionated Regimens: Fewer, larger fractions (2.5-4 Gy) compress treatment duration (2-4 weeks). This approach reduces overall treatment time and may improve compliance, though acute skin reactions are increased.

Efficacy in Different Malignancies

BCC: 90-95% complete response rates; 5-year recurrence 5-10%. Larger tumors (>2 cm) and infiltrative histology show higher recurrence. Radiation is particularly useful for infiltrative BCC where surgical margins would be unacceptably large.

SCC: 85-90% 5-year local control rates with superior outcomes for small-to-moderate tumors compared to other SCC subtypes. High-risk features (grade 3, >4 cm, poor differentiation) show reduced efficacy.

Melanoma: Adjuvant radiation after surgery for thick primary tumors (>4 mm Breslow) or nodal involvement reduces local recurrence by 50-70%. Overall survival benefit remains uncertain in some trials, though checkpoint inhibitors plus radiation show emerging promise. Radiosurgery (single high-dose focal radiation) is valuable for brain metastases.

Combination Approaches

Radiation + Immunotherapy: Radiation can enhance immunotherapy efficacy through tumor antigen release and immune cell activation (abscopal effect). Combining checkpoint inhibitors with radiation for advanced melanoma shows promising early data with improved outcomes compared to single modality.

Radiation + Targeted Therapy: BRAF/MEK inhibitors plus radiation for BRAF-mutant melanoma may provide synergistic benefit, though clinical data is limited.

Radiation + Topical Therapy: Combining radiation with topical 5-FU or imiquimod may enhance response for field cancerization, though data is sparse.

Acute and Late Adverse Effects

Acute Dermatitis: Erythema within 2-3 weeks; moist desquamation by 3-4 weeks. Managed with topical steroids and non-adherent dressings. Severe reactions may warrant dose reductions or treatment breaks.

Late Effects: Progressive fibrosis (6-24 months), telangiectasia (months-years), atrophy, and secondary malignancy (1-3% cumulative incidence). Younger patients and longer follow-up increase secondary malignancy risk.

FAQ

Q: Is radiation therapy painful?
A: Radiation itself is painless. Acute dermatitis causes discomfort; symptom management with topical steroids is usually sufficient.

Q: Will radiation cause hair loss?
A: Permanent alopecia develops within treated field after cumulative dose >25-30 Gy; hair outside field is unaffected.

Q: How does radiation compare to surgery?
A: Similar efficacy for small lesions. Surgery creates scars; radiation creates potential late fibrosis/atrophy. Individual patient factors guide selection.

Q: Can radiation be combined with other treatments?
A: Yes. Radiation + checkpoint inhibitors for melanoma shows promise. Radiation + topical therapy for NMSC is investigational.

Treatment Planning and Delivery

Modern radiation therapy for skin cancer employs several modalities tailored to tumor characteristics and location. Superficial radiation therapy (SRT) using 50-100 kV X-rays penetrates 1-5 mm, ideal for superficial BCC and SCC. Orthovoltage (100-300 kV) reaches deeper tumors up to 2 cm. Electron beam therapy provides uniform dose distribution with rapid dose fall-off, protecting underlying structures. Typical fractionation schedules include 50-70 Gy delivered in 25-35 fractions over 5-7 weeks for definitive treatment. Hypofractionated regimens (e.g., 45 Gy in 10 fractions) are used for elderly patients or palliative settings, achieving equivalent local control rates of 90-95% for BCC and 85-90% for SCC in multiple randomized trials.

Indications and Patient Selection

Primary radiation therapy is indicated when surgery would result in significant functional or cosmetic morbidity, particularly for tumors on the nose, eyelids, lips, and ears. It is preferred for patients who are poor surgical candidates due to anticoagulation, comorbidities, or advanced age. Adjuvant radiation is recommended after excision with close or positive margins, perineural invasion (especially nerves ≥0.1 mm diameter), and large or deeply invasive SCC. The NCCN guidelines recommend considering adjuvant radiation for high-risk cutaneous SCC with ≥2 risk factors including tumor size >2 cm, depth >6 mm, Clark level ≥IV, or immunosuppression.

References